Cargando…

Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft‐tissue sarcomas

Detalles Bibliográficos
Autores principales:	Blanchi, Julie, Taleb, Sofiane, Bayle, Arnaud, Verret, Benjamin, Toulmonde, Maud, Spalato‐ceruso, Mariella, Dubos, Paul, Laizet, Yech'an, Alame, Melissa, Khalifa, Emmanuel, Italiano, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508143/ https://www.ncbi.nlm.nih.gov/pubmed/37405935 http://dx.doi.org/10.1002/cac2.12461

Ejemplares similares

Gene expression profiling improves prognostication by nomogram in patients with soft‐tissue sarcomas
por: Crombé, Amandine, et al.
Publicado: (2022)

Targeting ERBB2 mutations in solid tumors: biological and clinical implications
por: Cousin, Sophie, et al.
Publicado: (2018)

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
por: Spalato-Ceruso, Mariella, et al.
Publicado: (2022)

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
por: Bayle, Arnaud, et al.
Publicado: (2023)

Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study
por: Blanchi, Julie, et al.
Publicado: (2023)

Clinical impact of extensive molecular profiling in advanced cancer patients
por: Cousin, Sophie, et al.
Publicado: (2017)

Local and Metastatic Relapse Features in Patients After a Primary Soft Tissue Sarcoma: Advocating for a Better-Tailored Follow-Up
por: Blaye, Céline, et al.
Publicado: (2019)

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications
por: Spalato-Ceruso, M, et al.
Publicado: (2023)

Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial
por: Italiano, Antoine, et al.
Publicado: (2021)

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome
por: Courtet, Kevin, et al.
Publicado: (2020)

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
por: Savina, Marion, et al.
Publicado: (2017)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

New frontiers in the medical management of gastrointestinal stromal tumours
por: Mazzocca, Alessandro, et al.
Publicado: (2019)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
por: Groothuis, Patrick, et al.
Publicado: (2021)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study
por: Verschoor, Arie Jan, et al.
Publicado: (2020)

Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor
por: Fu, Yu, et al.
Publicado: (2023)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
por: Cousin, Sophie, et al.
Publicado: (2022)

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

Targeting epigenetics in sarcomas through EZH2 inhibition
por: Italiano, Antoine
Publicado: (2020)

Establishing an RNA fusions panel in soft tissue sarcoma with clinical validation
por: Huang, Xiaoqiang, et al.
Publicado: (2023)

Development and validation of an RNA sequencing panel for gene fusions in soft tissue sarcoma
por: Hu, Wanming, et al.
Publicado: (2022)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database
por: Kantidakis, Georgios, et al.
Publicado: (2022)

OSIRIS: A Minimum Data Set for Data Sharing and Interoperability in Oncology
por: Guérin, Julien, et al.
Publicado: (2021)

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications
por: Ben-Ami, Eytan, et al.
Publicado: (2020)

Recent Advances in Desmoid Tumor Therapy
por: Napolitano, Andrea, et al.
Publicado: (2020)

ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
por: Laroche-Clary, Audrey, et al.
Publicado: (2020)

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas
por: Verbeke, S., et al.
Publicado: (2021)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015)

The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy
por: Crombé, Amandine, et al.
Publicado: (2022)

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
por: Roulleaux-Dugage, Matthieu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k2apungk9d798gi5iue55r1j5j